Sector Gamma AS boosted its position in shares of Takeda Pharmaceutical Co Ltd (NYSE:TAK) by 2.5% in the third quarter, according to the company in its most recent filing with the SEC. The firm owned 816,299 shares of the company’s stock after acquiring an additional 20,000 shares during the quarter. Takeda Pharmaceutical comprises about 2.4% of Sector Gamma AS’s portfolio, making the stock its 16th largest position. Sector Gamma AS’s holdings in Takeda Pharmaceutical were worth $14,040,000 at the end of the most recent reporting period.
Other institutional investors and hedge funds have also recently modified their holdings of the company. First Trust Advisors LP increased its stake in shares of Takeda Pharmaceutical by 23.3% in the 3rd quarter. First Trust Advisors LP now owns 2,041,133 shares of the company’s stock valued at $35,107,000 after purchasing an additional 385,573 shares in the last quarter. Mondrian Investment Partners LTD increased its stake in Takeda Pharmaceutical by 6.7% during the 3rd quarter. Mondrian Investment Partners LTD now owns 3,639,170 shares of the company’s stock worth $61,866,000 after buying an additional 229,000 shares in the last quarter. SRS Capital Advisors Inc. increased its stake in Takeda Pharmaceutical by 83.3% during the 3rd quarter. SRS Capital Advisors Inc. now owns 2,200 shares of the company’s stock worth $38,000 after buying an additional 1,000 shares in the last quarter. Parallel Advisors LLC increased its stake in Takeda Pharmaceutical by 276.3% during the 3rd quarter. Parallel Advisors LLC now owns 1,509 shares of the company’s stock worth $26,000 after buying an additional 1,108 shares in the last quarter. Finally, Yorktown Management & Research Co Inc purchased a new stake in Takeda Pharmaceutical during the 3rd quarter worth approximately $256,000. 4.67% of the stock is owned by institutional investors.
Several research firms have commented on TAK. ValuEngine lowered Takeda Pharmaceutical from a “hold” rating to a “sell” rating in a research note on Monday, November 4th. Cowen began coverage on Takeda Pharmaceutical in a research note on Friday, November 1st. They set a “market perform” rating and a $19.50 price objective for the company. Jefferies Financial Group assumed coverage on Takeda Pharmaceutical in a report on Tuesday, September 24th. They set a “buy” rating on the stock. Zacks Investment Research upgraded Takeda Pharmaceutical from a “sell” rating to a “hold” rating in a report on Tuesday, November 5th. Finally, Daiwa Capital Markets cut Takeda Pharmaceutical from an “outperform” rating to a “neutral” rating in a report on Thursday, August 15th. One equities research analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the company’s stock. Takeda Pharmaceutical presently has an average rating of “Hold” and a consensus price target of $19.25.
Shares of Takeda Pharmaceutical stock traded up $0.52 on Friday, hitting $20.07. 1,560,995 shares of the company were exchanged, compared to its average volume of 2,430,236. The stock has a market capitalization of $60.07 billion, a price-to-earnings ratio of 39.35 and a beta of 0.70. The company has a 50-day moving average price of $17.68 and a 200 day moving average price of $17.56. Takeda Pharmaceutical Co Ltd has a 1-year low of $15.50 and a 1-year high of $21.61. The company has a quick ratio of 0.94, a current ratio of 1.45 and a debt-to-equity ratio of 1.00.
Takeda Pharmaceutical (NYSE:TAK) last issued its earnings results on Thursday, October 31st. The company reported $0.59 earnings per share for the quarter. The business had revenue of $7.56 billion for the quarter. Takeda Pharmaceutical had a return on equity of 12.52% and a net margin of 3.66%. Research analysts forecast that Takeda Pharmaceutical Co Ltd will post 1.99 EPS for the current year.
Takeda Pharmaceutical Company Profile
Takeda Pharmaceutical Company Limited, together with its subsidiaries, engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. The company provides medicines in various therapeutic areas comprising gastroenterology, oncology, and neuroscience; and vaccines.
Featured Story: How Do I Invest in Dividend Stocks
Want to see what other hedge funds are holding TAK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Takeda Pharmaceutical Co Ltd (NYSE:TAK).
Receive News & Ratings for Takeda Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Takeda Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.